Trimetrexate Toxicity
Trimetrexate, a potent dihydrofolate reductase (DHFR) inhibitor, is an antimetabolite chemotherapeutic agent primarily used in the treatment of Pneumocystis jirovecii pneumonia (PCP) in immunocompromised patients, particularly those with HIV/AIDS. It has also been explored in various cancers including colorectal carcinoma and lymphomas. Despite its therapeutic potential, trimetrexate is associated with significant toxicity risks. This article